Results 131 to 140 of about 269,422 (292)

Neoadjuvant Cemiplimab for Resectable Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series

open access: yesHead &Neck, EarlyView.
ABSTRACT Introduction A Phase II trial demonstrated that neoadjuvant cemiplimab was associated with pathologic complete response (pCR) in 51% of patients with locoregionally advanced cutaneous squamous cell carcinoma (cuSCC). We evaluated real‐world radiographic and pathologic responses to neoadjuvant cemiplimab and assessed radiologic–pathologic ...
Whitney Jin   +14 more
wiley   +1 more source

GRAZAX®: a sublingual immunotherapy vaccine for Hay fever treatment: from concept to commercialization

open access: yesHuman Vaccines & Immunotherapeutics, 2019
Allergen immunotherapy has been used for more than 100 y, but only recently underlying immunological mechanisms have started to be understood. New Allergy vaccines are now considered to be full pharmaceutical products, that should comply with general as ...
Domingo Barber   +5 more
doaj   +1 more source

Allergen Release Profiles of Fast-Dissolving Freeze-Dried Orodispersible Sublingual Allergy Immunotherapy Tablets. [PDF]

open access: yesCurr Ther Res Clin Exp, 2022
Yamamoto T   +6 more
europepmc   +1 more source

Complete Pathologic Response to Neoadjuvant Pembrolizumab Captured on Intraoperative PET/CT: A Case Report and Exploratory Analysis

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Neoadjuvant immunotherapy is an emerging treatment for patients with head and neck cancer. Given the heterogeneity of response, novel methods of intraoperative tumor and margin assessment warrant investigation. Methods A 55‐year‐old male presented with a cT3N2c supraglottic squamous cell carcinoma with a combined positive score of 5.
Joaquin Austerlitz   +7 more
wiley   +1 more source

Rupatadine to prevent local allergic reactions to sublingual allergy immunotherapy: a case series. [PDF]

open access: yesAllergy Asthma Clin Immunol, 2021
Ellis AK   +3 more
europepmc   +1 more source

Characterization of Perineural Invasion Parameters for Risk Stratification in Oral Squamous Cell Carcinoma

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Perineural invasion (PNI) is an established adverse prognostic factor in oral squamous cell carcinoma (OSCC), but the implications of its extent as well as its relationship with surgical margin status and the extent of microscopic tumor spread remain unclear.
Michael A. Müller   +7 more
wiley   +1 more source

Allergy to goat’s and sheep’s milk in a population of cow’s milk–allergic children treated with oral immunotherapy*

open access: yes, 2012
Background: Cow's milk oral immunotherapy (CMOIT) is a recognized treatment for persistent cow's milk (CM) allergy. However, further data are necessary on tolerance to milk from other mammals.
Pérez‐Rangel, Inmaculada   +6 more
core   +1 more source

Prognostic Impact of Lymphovascular Invasion on Distant Metastasis in HPV‐Negative Head and Neck Cancer

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Lymphovascular invasion (LVI) is a recognized poor prognostic factor in head and neck squamous cell carcinoma (HNSCC), particularly for regional recurrence and overall survival. However, its role in predicting distant metastasis, especially in HPV‐negative HNSCC, remains unclear. Objective To evaluate the association between LVI and
Mark Khoury   +11 more
wiley   +1 more source

Need for longitudinal studies to assess the real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma - Authors´ reply. [PDF]

open access: yesLancet Reg Health Eur, 2022
Fritzsching B   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy